Loading
A phase 1/2 trial of Cyclophosphamide and Fludarabine in acute myeloid leukaemia and myelodysplastic syndromes / neoplasms, run by ARCE Therapeutics, Inc., now recruiting.
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS is a phase 1/2 interventional study registered as NCT06680752 by ARCE Therapeutics, Inc., with 49 participants planned, started 2025-05-20 and due to reach its primary completion in 2028-10. Interventions recorded: ARD103, Cyclophosphamide and Fludarabine.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Fludarabine, Cyclophosphamide and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Fludarabine, Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia and the tag pipeline.